Emerging novel therapies in the treatment of castrate-resistant prostate cancer. - Wikidata - awgldk - TriplyDB

Emerging novel therapies in the treatment of castrate-resistant prostate cancer.

Emerging novel therapies in the treatment of castrate-resistant prostate cancer.

http://www.wikidata.org/entity/Q37862392

about

Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.Refining the orthotopic dog prostate cancer (DPC)-1 model to better bridge the gap between rodents and men.Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice.Tapping the Potential of DNA Delivery with Electroporation for Cancer Immunotherapy.Les nouvelles du Réseau canadien du cancer de la vessie.Highlights from the canadian bladder cancer network.

P2860

Q37163756-07B0F0EA-B319-4B30-828D-4558321F638D Q38262816-584FC8D1-2674-4C79-8AB1-8463CDB6EC6A Q39481257-9563DC84-7620-42CD-A26A-01A9C94BF79A Q40644098-7E756E1D-AC71-466B-8F72-10291AE76276 Q41435861-0CDB144B-0E31-44F3-8CCE-ABE9FCDC9293 Q42156822-8280FC02-3B60-4988-9BE4-F6E0B760F2F8 Q42741606-8958B627-F062-4B86-8157-58E8D749B047

P2860

Emerging novel therapies in the treatment of castrate-resistant prostate cancer.

http://www.wikidata.org/entity/Q37862392

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Emerging novel therapies in the treatment of castrate-resistant prostate cancer.

@en

Emerging novel therapies in the treatment of castrate-resistant prostate cancer.

@nl

type

label

Emerging novel therapies in the treatment of castrate-resistant prostate cancer.

@en

Emerging novel therapies in the treatment of castrate-resistant prostate cancer.

@nl

prefLabel

Emerging novel therapies in the treatment of castrate-resistant prostate cancer.

@en

Emerging novel therapies in the treatment of castrate-resistant prostate cancer.

@nl

P1433

Q37862392-CF0291D7-F683-4C18-8FBE-E8E7901DD053

P1476

Q37862392-FB092F67-792B-482B-9419-9E9C0C2DE378

P2093

Q37862392-B90505D7-8BD9-4518-8AF9-1CC77CCF593D

Q37862392-D9D3F714-C49C-4E65-A5D5-449B2960B7C7

P2860

Q37862392-06C933A6-1D32-464D-99F4-2E96A62730F1

Q37862392-10643966-493D-4403-86B1-E45BD9B27F59

Q37862392-13667ABD-4711-4768-908E-61A4EF5D6811

Q37862392-1696AFC8-8F08-477F-AEB9-5213736F723B

Q37862392-2512ED1B-D10F-4A6D-BDE3-BFCF9D0D0B94

Q37862392-2A1FE71C-29B9-40F4-8872-396588EB07E0

Q37862392-3BAF02EC-E133-4D6D-90B6-62B78F4699EF

Q37862392-47940C74-EFAF-4B58-B32F-5C9A048FFEF0

Q37862392-51DCE07A-78A5-485D-B0BE-491F6231B610

Q37862392-5A57A62F-F0EF-4217-85DE-70DFC70F4153

P304

Q37862392-1E171C65-435C-443E-8405-7BAC65A0EEAB

P31

Q37862392-8898476E-6719-48FC-849D-56F6DAD80FAA

P356

Q37862392-F79C614F-8F0C-435A-98CE-E55492667DA6

P433

Q37862392-12E495D4-7039-4842-A1E5-7396AC91C4A3

P478

Q37862392-3CD22728-B589-41B2-ABD5-9FDA09BCD0AD

P577

Q37862392-72534DE2-C468-4C07-8AA6-CD65DFFB9555

P5875

Q37862392-47E791AF-6598-480C-96CA-EF7BF929795F

P698

Q37862392-17668DF0-1B62-4CB5-9A5A-A307DDD9CF87

P932

Q37862392-0C78E089-6022-407D-86F5-06A056CB0B67

P356

P1433

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

P1476

Emerging novel therapies in the treatment of castrate-resistant prostate cancer.

@en

P2093

Alym Abdulla

http://www.w3.org/2001/XMLSchema#string

Anil Kapoor

http://www.w3.org/2001/XMLSchema#string

P2860

Src family kinases in tumor progression and metastasis

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

The endothelin axis: emerging role in cancer

FYN is overexpressed in human prostate cancer

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?

P304

120-133

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5489/CUAJ.10160

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51029868

http://www.w3.org/2001/XMLSchema#string

P698

21470540

http://www.w3.org/2001/XMLSchema#string

P932

3104424

http://www.w3.org/2001/XMLSchema#string